RANDOMIZED TRIAL OF CONCURRENT VERSUS SEQUENTIAL DOCETAXEL PLUS BORTEZOMIB ( PS-341) IN PLATINUM-TREATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): A CALIFORNIA CANCER CONSORTIUM STUDY

被引：0

作者：

Lara, P. N.

Longmate, J.

Argiris, A. ^{[1
]}

Gitlitz, B. ^{[2
]}

Mack, P. C. ^{[3
]}

Lau, D.

Koczywas, M.

Leighl, N. B. ^{[4
]}

Gandara, D. R. ^{[5
]}

机构：

[1] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA

[2] Univ So Calif, Los Angeles, CA USA

[3] Univ Calif Davis, Dept Internal Med Hematol Oncol, Sacramento, CA 95817 USA

[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[5] Univ Calif Davis, Ctr Canc, Dept Internal Med Hematol Oncol, Sacramento, CA 95817 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S81 / S81

页数：1

共 50 条

[21] Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
Gandara, DR
Vokes, E
Green, M
Bonomi, P
Devore, R
Comis, R
Carbone, D
Karp, D
Belani, C
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 131 - 135
[22] Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Wang, Z.
Han, X.
Guo, J.
Zhu, D.
Zhang, X.
Tang, X.
Meng, X.
ANNALS OF ONCOLOGY, 2020, 31 : S1400 - S1400
[23] A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer
Lee, Jae Jin
Han, Ji-Youn
Lee, Dae Ho
Kim, Hyae Young
Chun, Jong Ho
Lee, Hong Gi
Yoon, Seong Min
Lee, Sung Young
Lee, Jin Soo
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (12) : 761 - 767
[24] Weekly docetaxel versus docetaxel/gemcitabine in elderly/poor performance status (PS) patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC): Randomized phase III trial of the Minnie Pearl Cancer Research Network
Greco, F. A.
Spigel, D. R.
Burris, H. A., III
Shipley, D. L.
Farley, C.
Gandhi, J.
Houston, G. A.
Hainsworth, J. D.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[25] Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
Heist, Rebecca Suk
Aren, Osvaldo Rudy
Mita, Alain C.
Polikoff, Jonathan
Bazhenova, Lyudmila
Lloyd, G. Kenneth
Mikrut, William
Reich, Steven D.
Spear, Matthew A.
Huang, Lan
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[26] A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC).
Lilenbaum, R
Rubin, M
Samuel, J
Boros, L
Chidiac, T
Seigel, L
Graham, P
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 630S - 630S
[27] Phase II study of weekly docetaxel and gemcitabine in relapsed patients (pts) with advanced, platinum-exposed non-small cell lung cancer (NSCLC)
Langer, C. J.
Huang, C.
Ruth, K.
Shafer, D.
Borghaei, H.
Millenson, M.
Mintzer, D.
Staddon, A.
Seldomridge, J.
Tuttle, H.
Treat, J.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[28] Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increased response in non-small cell lung carcinoma (NSCLC).
Gumerlock, PH
Moisan, LP
Lau, AH
Mack, PC
Lara, PN
Gandara, DR
CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3809S - 3810S
[29] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III randomized trial
Georgoulias, V.
Ardavanis, A.
Tsiafaki, X.
Agelidou, A.
Syrigos, K.
Polyzos, A.
Kakolyris, S.
Kouroussis, Ch
Androulakis, N.
Chatzidaki, D.
ANNALS OF ONCOLOGY, 2004, 15 : 169 - 169
[30] Celecoxib (CEL) and weekly docetaxel (DOC) in elderly or PS2 patients (pts) with advanced non-small cell lung cancer (NSCLC).
Chaplan, RA
Kalemkerian, GP
Wozniak, A
Shehadeh, N
Ruckdeschel, JC
Kraut, MJ
Heilbrun, L
Parchment, R
Gadgeel, SM
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 641S - 641S

← 1 2 3 4 5 →